Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome
- 52 Downloads
While the metabolic syndrome (MS) is being recognized as an important risk factor for intrahepatic cholangiocarcinoma (ICC), the outcomes of liver resection in this context remain poorly described. This study aims to report the short- and long-term results of hepatectomy for patients with MS as risk factor for the development of ICC (MS+).
All patients undergoing hepatectomy for ICC between 2000 and 2016 at a single center were retrospectively analyzed. The perioperative outcomes of MS+ and ICC patients without MS (MS−) were compared.
Among 115 resected ICC patients, 40 (34.8%) were MS+ and 75 (65.2%) were MS−. MS+ exhibited an increased Charlson comorbidity index (5 ± 2 vs. 2 ± 2, p < 0.001) than MS− patients. While operative characteristics did not differ significantly between the 2 groups, MS+ experienced higher rate of major complications (62.5 vs. 29.3%, p = 0.001). On multivariate analysis, MS+ was an independent risk factor of major complication (HR 2.86, 95% CI 1.07–7.60, p = 0.036) and major cardiorespiratory complication (HR 4.35, 95% CI 1.50–12.62, p = 0.007). Pathological analysis revealed that MS+ displayed higher rates of non-alcoholic fatty liver disease (60.0 vs. 31.1%, p = 0.003) and non-alcoholic steatohepatitis (25 vs. 5.4%, p = 0.005). MS+ was independently associated with decreased risk of recurrence (HR 0.47, 95% CI 0.26–0.85, p = 0.001).
MS+ accounts for 35% of resected ICC patients. The existence of significant cardiovascular comorbidities increases postoperative morbidity and requires specific management.
Compliance with ethical standards
Conflict of interest
None of the authors have any conflict of interest of any kind.
- 17.Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefGoogle Scholar
- 23.Ishizawa T, Hasegawa K, Kokudo N, Sano K, Imamura H, Beck Y et al (2009) Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg Chic Ill 1960 144(1):46–51Google Scholar
- 28.WHO classification of tumours of the digestive system, 4th edn-WHO-OMS. Disponible sur: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4003
- 29.AJCC Cancer Staging Manual|Mahul B. Amin|Springer. Disponible sur: http://www.springer.com/us/book/9783319406176
- 32.Bedossa P, FLIP Pathology Consortium (2014) Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatol Baltim Md 60(2):565–575CrossRefGoogle Scholar
- 42.Cai X, Liang X, Yu T, Liang Y, Jing R, Jiang W et al (2015) Liver cirrhosis grading Child-Pugh class B: a Goliath to challenge in laparoscopic liver resection?-prior experience and matched comparisons. Hepatobiliary Surg Nutr 4(6):391–397Google Scholar